Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to provide information about the bone-anabolic response of PTH134 when
administered orally, in comparison to Forsteo®, the sub-cutaneous form of teriparatide, the
active ingredient in PTH134.